Kyle Kuvalanka

Director of Finance/CFO at AKTIS ONCOLOGY, INC.

57 year

Health Technology

Consumer Services

Profile

Kyle D.
Kuvalanka is Chief Financial Officer at Aktis Oncology, Inc. since 2025.
Former roles include Independent Director at IMV, Inc. from 2021 to 2023; Chief Operating & Financial Officer at Goldfinch Bio, Inc. from 2020 to 2023; Chief Financial Officer & Chief Business Officer at Rome Therapeutics, Inc.; Chief Operating, Financial & Accounting Officer at Syros Pharmaceuticals, Inc. from 2015 to 2017; CFO, Treasurer, CAO & Chief Business Officer at Blueprint Medicines Corp.
from 2013 to 2015; Vice President-Strategy & Business Development at Millennium Pharmaceuticals, Inc. from 2012 to 2013.
Education includes undergraduate studies at Wesleyan University and an MBA from The Wharton School of the University of Pennsylvania.

Kyle Kuvalanka active positions

Companies	Position	Start
AKTIS ONCOLOGY, INC.	Director of Finance/CFO	2025-10-31

All active positions of Kyle Kuvalanka

Former positions of Kyle Kuvalanka

Companies	Position	End
IMV INC.	Director/Board Member	2023-08-31
Goldfinch Bio, Inc. Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Develop medicines and therapies for patients with kidney disease	Director of Finance/CFO	2023-03-31
SYROS PHARMACEUTICALS, INC.	Director of Finance/CFO	2017-09-21
BLUEPRINT MEDICINES CORPORATION	Director of Finance/CFO	2015-09-17
Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment	Corporate Officer/Principal	2013-08-31

See the detail of Kyle Kuvalanka's experience

Training of Kyle Kuvalanka

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kyle Kuvalanka's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	9
Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment	Health Technology
Wesleyan University Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
IMV, Inc. IMV, Inc. BiotechnologyHealth Technology Operates as a clinical-stage immuno-oncology company	Health Technology
Blueprint Medicines Corp. Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer	Health Technology
Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which developing care for the frontline treatment of patients with hematologic malignancies	Health Technology
The Wharton School of the University of Pennsylvania The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Goldfinch Bio, Inc. Goldfinch Bio, Inc. Pharmaceuticals: MajorHealth Technology Develop medicines and therapies for patients with kidney disease	Health Technology
Rome Therapeutics, Inc. Rome Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops novel therapies for cancer and autoimmune diseases	Health Technology
Aktis Oncology, Inc. Aktis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops and discovers radiopharmaceuticals to treat tumor cancers	Health Technology